Oncology Firms Collaborate to Increase Patient Access to Clinical Trials

EmploymentCrossing


Philadelphia-based Radiation Therapy Oncology Group and Houstons US Oncology have announced a collaboration to increase patient access to national cancer clinical trials, with a radiation focus in the community setting.

The collaboration means patients receiving cancer care at practices affiliated with US Oncology have access to RTOG trials for disease sites including brain, head & neck, lung, gastrointestinal, genitourinary, cervix, and breast cancers. RTOG trials focus on testing the integration of radiation therapy with new systemic therapies and surgery.

"Our collaboration with US Oncology and its network of member practices is attractive due to the organization's strong commitment to clinical trial participation, leadership and accrual," said Walter Curran, MD, Group Chairman of RTOG and professor and chairman of the Department of Radiation Oncology of Emory University School of Medicine.

The collaboration provides RTOG access to US Oncology's significant patient population, making radiation therapy trials more accessible to cancer patients in the community setting nationwide.

The RTOG is a clinical research enterprise of the American College of Radiology. It has 40 years of experience in conducting clinical trials and is comprised of over 300 major research institutions in the United States, Canada, and internationally.

US Oncology works closely with physicians, manufacturers and payers to identify and deliver services that enhance patient access to advanced cancer care.

Category:

News & Politics

Tags:

• videos
• oncology
• radiation
• therapy
• cancer
• Emory
• University
• School
• of
• Medicine
• RTOG

[robert80taylor]

“Unnecessary risks are being taken by patients seeking the liberation treatment.” says Dr. Avneesh Gupte of the CCSVI Clinic. “It has been our contention since we started doing minimally invasive venous angioplasties nearly 6 years ago that discharging patients who have had neck vein surgery on an outpatient basis is contra-indicated. For more information Log on to ccsviclinic.ca OR Call on Toll Free: 888-419-6855.

[robert80taylor]

We have been keeping patients hospitalized for a week to 10 days as a matter of safety and monitoring them for symptoms. Nobody who has the liberation therapy gets discharged earlier than that. During that time we do daily Doppler Ultrasounds, blood work and blood pressure monitoring among other testing. For more information Log on to ccsviclinic.ca OR Call on Toll Free: 888-419-6855.

[robert80taylor]

This has been the safe practice standard that we have adopted and this post-procedure monitoring over 10 days is the subject of our recent study as it relates to CCSVI for MS patients.” For more information Log on to ccsviclinic.ca OR Call on Toll Free: 888-419-6855.